GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Probability of Financial Distress (%)

Beijing Bohui Innovation Biotechnology Group Co (SZSE:300318) Probability of Financial Distress (%) : 0.03% (As of Mar. 30, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Bohui Innovation Biotechnology Group Co Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%) is 0.03%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%)

For the Biotechnology subindustry, Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%) falls into.


;
;

Beijing Bohui Innovation Biotechnology Group Co Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-8.05

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.03%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Beijing Bohui Innovation Biotechnology Group Co  (SZSE:300318) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Beijing Bohui Innovation Biotechnology Group Co Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Beijing Bohui Innovation Biotechnology Group Co's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Bohui Innovation Biotechnology Group Co Business Description

Traded in Other Exchanges
N/A
Address
Block G Jingxinyuan, NO.25 Jia Beiwucun Road, Haidian, Beijing, CHN, 100097
Beijing Bohui Innovation Biotechnology Group Co Ltd is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. The company focuses on the research and development, production, sales, and after-sales services of in vitro diagnostic products. The Company's business involved two segments: inspection and testing and biological products. The Biological segment generated the majority of its revenue which engaged in the research and development, production, and sales of blood products, the product range covers human blood albumin, human immunoglobulin, and human coagulation factor three categories of multiple varieties, basically covering the important varieties of blood products.
Executives
Niu Shu Hui Executives
Di Xiao Feng Director
Yang Qi Director
Lu Xin Qun Directors, executives
Zhang Lei Director
Wan Zhang Geng Executives
Song Rui Directors, executives

Beijing Bohui Innovation Biotechnology Group Co Headlines

No Headlines